Medicure Inc. (CVE:MPH – Get Free Report)’s share price passed above its fifty day moving average during trading on Tuesday . The stock has a fifty day moving average of C$1.12 and traded as high as C$1.15. Medicure shares last traded at C$1.15, with a volume of 4,000 shares trading hands.
Medicure Stock Down 2.5%
The firm has a 50-day moving average price of C$1.12 and a 200 day moving average price of C$1.17. The company has a debt-to-equity ratio of 6.90, a current ratio of 1.02 and a quick ratio of 1.29. The company has a market cap of C$12.00 million, a price-to-earnings ratio of -1.69 and a beta of 0.62.
Medicure Company Profile
Medicure Inc, a biopharmaceutical company, engages in the research, development, and commercialization of human therapies in the United States. The company markets and distributes AGGRASTAT injection, a glycoprotein GP IIb/IIIa receptor antagonist for the treatment of acute coronary syndrome, including unstable angina and non-Q-wave myocardial infarction. It also offers ZYPITAMAG to treat patients with primary hyperlipidemia or mixed dyslipidemia. In addition, the company is developing Sodium Nitroprusside injection, and Generic ANDA 2 and 3 for acute cardiology; and TARDOCAL, to treat neurological indications.
See Also
- Five stocks we like better than Medicure
- Navy Catalyst Ignites Odysight’s Growth Engine
- AST SpaceMobile Plummets on Galactic Q1 Miss: Can Vertical Integration Save the SpaceX Rival?
- Axon Surged After Earnings and Is Still Down Over 50% From Highs
- The Event That Could Redefine Apple’s Summer Rally
Receive News & Ratings for Medicure Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medicure and related companies with MarketBeat.com's FREE daily email newsletter.
